drugset / Trial / NCT05488067

Atorvastatin Therapy on Xanthoma in Alagille Syndrome

NCT05488067 ↗

Phase 4 Completed 15 enrolled Children's Hospital of Fudan University
NaSingle-groupOpen-labelTreatment

Summary

To observe the efficacy and safety of atorvastatin on xanthoma in Alagille syndrome through a prospective study.

Timeline

Start
2022-03-22
Primary completion
2024-08-01
Completion
2024-08-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 0.33 mg/kg Oral
Subject Atorvastatin Small molecule 1 mg/kg Oral
Subject Atorvastatin Small molecule 1.25 mg Oral
Subject Atorvastatin Small molecule 2.5 mg Oral
Subject Atorvastatin Small molecule 5 mg Oral
Subject Atorvastatin Small molecule 10 mg Oral